Navigation Links
Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
Date:7/25/2013

title="Asleep at the Wheel" onclick="linkClick(this.href)">Asleep at the Wheel, Ray Benson, and other Texas musicians yet to be announced.

View the Indiegogo campaign at http://www.indiegogo.com. Follow it on Twitter: http://www.twitter.com/anyorgananybody and Facebook: http://www.facebook.com/AnyOrganAnyBody.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, L.L.C. (“PTS”) was founded in 2003 by Dr. William Hildebrand, Presbyterian Health Foundation Endowed Professor and the Robert Glenn Rapp Foundation Presidential Professor in the Department of Microbiology and Immunology at The University of Oklahoma Health Sciences Center. Dr. Hildebrand and his team have created a game-changing immunotherapeutic combination medical device for use in a novel selective antibody removal therapy based on thirteen years of expertise in HLA production and application development. This immunotherapeutic device called the HLA-ARCTM (or simply the ARC) is a selective HLA Antibody Removal Column that has the ability to selectively remove only those anti-HLA antibodies that are deleterious to the individual’s transplanted organ or bone marrow. PTS is a subsidiary of Pure Protein L.L.C, a company that has developed and patented several soluble HLA protein technology methods. Visit http://www.pureproteinllc.com for more information.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10958505.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
2. Universal Stem Cell Product Could Overcome Key Challenges in Donor Organ Transplants
3. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
4. Researchers identify signals that direct the immune system to reject a transplanted organ
5. Stem cell transplant restores memory, learning in mice
6. Stem cells produce compact, regenerated bone in mandible transplants
7. Transplanted brain cells in monkeys light up personalized therapy
8. Stem Cells Show Promise in Extending Transplanted Kidneys’ Survival Time
9. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
10. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
11. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 7 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... the fiscal year ended December 31, 2007., ... its EAA(TM) Endotoxin,Activity Assay, the only FDA ... is a systemic response to bacterial toxins ...
... CLARA, Calif., March 7 Finesse Solutions, LLC, ... sciences process,applications, and Nova Biomedical, Waltham, MA, a ... TruBio(TM) OS plug-in,for OPC connectivity between TruBio(TM) OS ... Basic 2 analyzers. Both companies confirmed that a,TruBio(TM) ...
... SAN DIEGO, March 6 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... will release its,fourth quarter and full year ended ... market on Wednesday, March 12, 2008., Cadence ...
Cached Biology Technology:Spectral announces 2007 financial results 2Spectral announces 2007 financial results 3Spectral announces 2007 financial results 4Spectral announces 2007 financial results 5Spectral announces 2007 financial results 6Spectral announces 2007 financial results 7Spectral announces 2007 financial results 8Spectral announces 2007 financial results 9Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008 2
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... Ore. In ecosystems around the world, the decline of ... is changing the face of landscapes from the tropics to ... published today in the journal Science shows for ... by humans and loss of prey combine to create global ...
... A team of scientists at LSU Health Sciences Center ... of E6-associated protein (E6AP), an enzyme that acts as a ... time, that the active form of E6AP is composed of ... the ability of nerve cells to "rewire" themselves in response ...
... new technology to squeeze more energy from the fuel release ... power plants do, according to a new analysis accepted for ... of the American Geophysical Union. The so-called "combined cycle" natural ... sulfur dioxide, which can worsen air quality. "Since more ...
Cached Biology News:Loss of large carnivores poses global conservation problem 2Loss of large carnivores poses global conservation problem 3LSUHSC research reveals structure of master regulator and new drug target for autism, cervical cancer 2New study: US power plant emissions down 2
See product name for description....
Request Info...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Biology Products: